Assessment of pharmacokinetic interactions of the HCV NS5A replication complex inhibitor daclatasvir with antiretroviral agents: ritonavir-boosted atazanavir, efavirenz, and tenofovir
Publication Type:
Journal Article
Authors:
Bifano, M.;
Hwang, C.;
Oosterhuis, B.;
Hartstra, J.;
Grasela, D.;
Tiessen, R.;
Velinova-Donga, M.;
Kandoussi, H.;
Sevinsky, H.;
Bertz, R.Source:
Antivir Ther, Volume 18, Issue 7, p.931-940 (2013)
Keywords:
Adenine,
administration & dosage,
Adolescent,
Adult,
adverse effects,
analogs & derivatives,
antagonists & inhibitors,
Anti-HIV Agents,
Antiretroviral,
Antiretrovirals,
atazanavir,
Benzoxazines,
clinical trial,
coinfection,
Drug Interactions,
drug therapy,
efavirenz,
Female,
HCV,
hepatitis,
Hepatitis C,
hepatitis C virus,
HIV Infections,
Humans,
Imidazoles,
Infection,
Male,
methods,
Middle Aged,
Oligopeptides,
Organophosphonates,
pharmacokinetic,
pharmacokinetics,
Proteins,
Pyridines,
Research,
Research Support,
ritonavir,
tenofovir,
treatment,
Viral Nonstructural Proteins,
Young Adult
